News

News 03.06.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it...

News 31.05.2024 ZURICH, Switzerland and NEWTON, Massachusetts, May 30, 2024 — GlobeNewswire — Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible,...

News 23.05.2024 Innovate UK (iUK), the United Kingdom (UK)'s national innovation agency, and Innosuisse, the Swiss counterpart, are co-founding a project to enhance innovation in cell and gene therapy (CGT) manufacturing. The project consortium includes Cell and Gene Therapy Catapult Limited from the UK, and Securecell AG, and DataHow AG from Switzerland. The...

News 21.05.2024 Switzerland, 17 May 2024 – CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, is glad to announce the first closing of CHF 25 million in its Series C funding round. This milestone demonstrates strong investor confidence in CUTISS’ mission and progress. The Series...

News 17.05.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or...